A preliminary double-blind study with SB 5833 (camazepam), a new benzodiazepine derivative.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy; D002219:Carbamates / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D003975:Diazepam / Q000031:analogs & derivatives / Q000627:therapeutic use; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D008297:Male; D011569:Psychiatric Status Rating Scales
D014151:Anti-Anxiety Agents; D002219:Carbamates; D003975:Diazepam